RedHill Biopharma Ltd. (NASDAQ:RDHL) has been given a $33.00 price objective by investment analysts at HC Wainwright in a research note issued to investors on Friday. The firm currently has a a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 128.06% from the company’s previous close.
Other equities research analysts have also issued research reports about the company. FBR & Co reissued a “buy” rating on shares of RedHill Biopharma in a research report on Friday, September 9th. Zacks Investment Research raised RedHill Biopharma from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research report on Tuesday, June 28th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $26.20.
Shares of RedHill Biopharma (NASDAQ:RDHL) opened at 14.47 on Friday. The stock’s market cap is $184.26 million. RedHill Biopharma has a 52-week low of $8.10 and a 52-week high of $16.54. The firm has a 50-day moving average price of $14.67 and a 200 day moving average price of $12.80.
RedHill Biopharma (NASDAQ:RDHL) last issued its earnings results on Wednesday, July 27th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.52. Analysts expect that RedHill Biopharma will post ($2.06) earnings per share for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Van ECK Associates Corp raised its position in RedHill Biopharma by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock valued at $105,000 after buying an additional 138 shares during the period. Ingalls & Snyder LLC purchased a new position in RedHill Biopharma during the second quarter valued at approximately $451,000. Oppenheimer & Co. Inc. purchased a new position in RedHill Biopharma during the second quarter valued at approximately $142,000. Finally, Royal Bank of Canada raised its position in RedHill Biopharma by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock valued at $259,000 after buying an additional 191 shares during the period. 15.30% of the stock is currently owned by institutional investors.
RedHill Biopharma Company Profile
Receive News & Ratings for RedHill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.